FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells by Sturla, L-M et al.
FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates
growth is frequently expressed in tumour cells
L-M Sturla1,2, AE Merrick1 and SA Burchill*,1
1Candlelighter’s Children’s Cancer Research Laboratory, Cancer Research UK Clinical Centre, St. James’s University Hospital, Beckett Street,
Leeds LS9 7TF, UK
Fibroblast growth factor receptor 3 (FGFR3) is one of four high-affinity tyrosine kinase receptors for the FGF family of ligands,
frequently associated with growth arrest and induction of differentiation. The extracellular immunoglobulin (IgG)-like domains II and III
are responsible for ligand binding; alternative usage of exons IIIb and IIIc of the Ig-like domain III determining the ligand-binding
specificity of the receptor. By reverse transcriptase polymerase chain reaction (RT–PCR) a novel FGFR3IIIc variant FGFR3IIIS,
expressed in a high proportion of tumours and tumour cell lines but rarely in normal tissues, has been identified. Unlike recently
described nonsense transcripts of FGFR3, the coding region of FGFR3IIIS remains in-frame producing a novel protein. The protein
product is coexpressed with FGFR3IIIc in the membrane and soluble cell fractions; expression in the soluble fraction is decreased after
exposure to bFGF but not aFGF. Knockout of FGFR3IIIS using antisense has a growth-inhibitory effect in vitro, suggesting a dominant-
negative function for FGFR3IIIS inhibiting FGFR3-induced growth arrest. In summary, alternative splicing of the FGFR3 Ig-domain III
represents a mechanism for the generation of receptor diversity. FGFR3IIIS may regulate FGF and FGFR trafficking and function,
possibly contributing to the development of a malignant phenotype.
British Journal of Cancer (2003) 89, 1276–1284. doi:10.1038/sj.bjc.6601249 www.bjcancer.com
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The fibroblast growth factor (FGF) signal transduction occurs via a
family of low- and high-affinity receptors. The high-affinity
receptors are tyrosine kinase receptors encoded by four genes,
with alternative splicing of their respective mRNAs generating
many fibroblast growth factor receptor (FGFR) isoforms. They rely
on the same core structure of an extracellular domain comprising
an amino terminal hydrophobic signal peptide followed by three
immunoglobulin (Ig)-like loops, a single hydrophobic transmem-
brane sequence and an intracellular split-tyrosine kinase domain.
The ligand-binding site is confined to the extracellular Ig-like
domains II and III (Avivi et al, 1993). The c-terminal half of Ig-
domain III is encoded by two separate exons, exon 8 (IIIb) and
exon 9 (IIIc); alternative usage of these exons determines the
ligand-binding specificity of the receptor. The receptors and their
respective alternatively spliced isoforms are expressed in a cell-
and tissue-specific manner, important for initiating specific
responses to the ubiquitously expressed FGF family of growth
factors. It is now evident that the inappropriate expression of some
isoforms can contribute to malignant progression (Morrison et al,
1994, Yamaguchi et al, 1994).
FGFR3 is normally expressed in the tissues of the central
nervous system, brain, kidney and testis, but not in the spleen,
heart or muscle (Cancilla et al, 1999; Plowright et al, 2000). Mis-
sense mutations in the transmembrane region of FGFR3 result in
constitutive activation and the autosomal dominant heritable
disorders of skeletal development such as thanatophoric dwarfism,
achondroplasia and Crouzon syndrome (Tavormina et al, 1995;
Naski et al, 1996; Bonaventure et al, 2001). The phenotype
observed in dwarfism suggests that the dysregulation of FGFR3
could impair cell growth and differentiation (Su et al, 1997; Legeai-
Mallet et al, 1998; Sahni et al, 1999), knockout mouse studies
confirming an inhibitory role for FGFR3 in bone growth (Colvin
et al, 1996; Deng et al, 1996). However, FGFR3 may regulate
differentiation (Kobrin et al, 1993; Kanai et al, 1997) or apoptosis
(Plowright et al, 2000) dependent on the tissue type, consistent
with a multifunctional role of FGFR3. FGFR3 normally exists in
two forms, FGFR3IIIc and FGFR3IIIb, which arise following
alternative splicing in which either exon 8 or 9 respectively are
skipped. Little is known about FGFR3IIIc and its isoforms,
although it is expressed in ovarian cancers where it is activated
by FGF8 (Valve et al, 2000). However, FGFR3IIIb is the
predominant form expressed in epithelial cells and epithelial-
derived tumours such as colorectal cancer (Murgue et al, 1994;
Jang et al, 2000). Recent studies suggest that the dysregulation of
FGFR3IIIb mRNA splicing generates aberrant transcripts that may
confer a selectable survival or growth advantage for colorectal
cancer cells (Jang et al, 2000). Typically, the predicted transcrip-
tion products exhibit a frame-shift and premature termination in
exon 10, so no functional protein product is translated (Jang et al,
2000). Where mutations of FGFR3 are frequent events, forReceived 20 January 2003; revised 2 July 2003; accepted 8 July 2003
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example, in bladder cancer (Cappellen et al, 1999; Billerey et al,
2001; van Rhijn et al, 2001; Sibley et al, 2001), nonsense mutations
inserted within its coding region may result in altered splice site
selection (Valentine, 1998). This is unlikely to be the case for the
majority of cancers where mutations of FGFR3 are rare (Intini et al,
2001; Karoui et al, 2001; Sibley et al, 2001), although FGFR3 may
be inactivated by aberrant-splicing and activation of cryptic splice
donor sites (Jang et al, 2000). In this study we have identified and
characterised a novel FGFR3IIIc variant, FGFR3IIIS, which is
frequently expressed in tumorigenic but rarely in nontumorigenic
cells. This variant is identical to FGFR3IIIc except for a 336 bp
deletion resulting in loss of exons 9 and 10, and a 30 bp deletion in
exon 7. FGFR3IIIS mRNA encodes a protein product that is co-
expressed with full-length FGFR3IIIc in the membrane and soluble
cell fraction. The expression and localisation of FGFR3IIIS and
FGFR3IIIc are modulated by exposure to bFGF but not aFGF.
FGFR3IIIS is not phosphorylated following exposure to bFGF or
aFGF, but it may modulate dose-dependent ligand-induced
phosphorylation of FGFR3IIIc. Furthermore, knockout of
FGFR3IIIS decreases viable cell number, consistent with a
dominant-negative role for FGFR3IIIS inhibiting FGFR3IIIc-
induced growth arrest and differentiation.
MATERIALS AND METHODS
Cell lines
The following 19 cell lines (all cell lines were of human origin
except the PC12 cells) were studied—two neuroblastoma (SK-N-
SH and IMR-32), six tumours of the Ewing’s sarcoma family
(ESFTs)(TC-32, RD-ES, A673, SK-N-MC, SKES1 and TTC-466), a
neurofibrosarcoma (ST118), two rhabdomyosarcoma (RH30 and
CCL136), two bladder cancer (RT112 and EJ), a melanoma (VUP),
prostate carcinoma (LNCAP), a colorectal carcinoma (HT29), a
breast cancer (MCF7), a myeloma (U266) and a rat adrenal
pheochromocytoma (PC12). TC-32 and RD-ES cells were a kind
gift from Dr J Toretsky (National Institute of Cancer, Bethesda,
USA), and TTC-466 was a gift from Dr PHB Sorenson (British
Columbia Children’s Hospital, Vancouver, Canada). All other cell
lines were obtained from the American Tissue Culture Collection.
Cell lines were grown in standard growth media plus 10% FCS at
371C in 5% CO2: 95% air; growth media for TTC-466 and U266
cells was supplemented with 10% conditioned media.
Tumour samples
A total of 30 tumours were studied; nine neuroblastoma, 12 ESFTs,
two Wilms’ tumours, two rhabdomyosarcomas, one astrocytoma
and four medulloblastomas. All patients were treated at St James’s
University Hospital between 1992 and 1998. Histological and
genetic diagnosies were made according to conventional criteria.
All tumour specimens were obtained in accordance with the Leeds
Teaching Hospital Trust Ethics Committee; samples were taken at
diagnosis, with the exception of one neuroblastoma taken post-
treatment, one neuroblastoma and one Ewing’s sarcoma taken at
relapse. Tumour biopsies were snap-frozen in liquid nitrogen at
the time of surgery and stored at 801C prior to analysis.
Detection of FGFR3 splice-variants by reverse
transcriptase–polymerase chain reaction (RT –PCR)
The total cellular RNA from cultured cells, tumours and tissues
was isolated using Ultraspect (Biogenesis, Poole, UK), and
amplified by reverse transcriptase-polymerase chain reaction
RT–PCR (Burchill et al, 1994) for FGFR3. Primer sequences for
PCR were chosen within exons 3 and 4 to amplify the first Ig-like
loop of the extracellular domain (50- ATTCGGGATGTGGAGCTG-
GAAGTGC-30, 50- TGAAACATTGACGGAGAAGTAGGTG-30; pri-
mer set 1) and within exons 6 and 12 (50-GAGAACAAGTTT-
GGCAGCATCC-30, 50-GCCCGAGACAGCTCCCATTTGG-30; primer
set 2) to amplify the third Ig-like loop and the transmembrane/
tyrosine kinase domain.
RNA isolated from MCF-7 cells was used as a positive control; a
negative control containing no reverse transcriptase was included
to confirm that the amplified products were generated from cDNA
rather than contaminating genomic DNA (reverse transcriptase
negative control) and a PCR negative control in which there was no
nucleic acid was included to control for contamination
(water control). Further analysis of the FGFR3IIIc variant in
normal cDNAs and RNAs was made by amplification using a
primer specific to FGFR3IIIS sequence (exon 7/11 splice site),
paired with a primer at the 50 (exon 2; 50-GACGCCGCGGC-
CCCCGCCCCCGCCA -30) or 30 (exon 17; 50-AGAGCAGGACCC-
CAAAGGACCAGAC -30; primer set 3) ends of the published wild-
type sequence. Amplified products (30 ml) were separated by
agarose gel electrophoresis (1% agarose in 1TBE), gels were
stained with ethidium bromide (0.5mg ml1) and visualised under
UV light. Products were excised from the gel and DNA extracted
using the QIAquick gel extraction kit (QIAGEN Ltd, Crawley, UK).
Each amplified product (approximately 50 ng) was sequenced
using the ABI PRISM Big dye terminator kit (Perkin-Elmer,
Applied Biosciences Ltd, Warrington, UK) and an ABI 377
automated sequencer. PCR primers (1.6 pmol per reaction) were
used as forward and reverse sequencing primers.
Southern blotting of PCR products
PCR products, separated by size on agarose gels, were transferred
on to a Hybond-Nþ nitrocellulose membrane (Amersham,
Biosciences (UK) Ltd, Bucks, UK) and probed with an FGFR3IIIS
specific riboprobe. The riboprobe was generated by cloning the
FGFR3IIIS PCR product amplified from MCF7 cells into the
pCRs2.1-TOPO vector (Invitrogen, Leek, Netherlands) and
transcribing using the Riboprobes in vitro transcription system
(Promega, Southampton, UK). Membranes were prehybridised at
421C for 2 h in a hybridisation solution (50% formamide, 0.02%
SDS, 0.1% N-laurylsarcosine, 5 SSC, 5% blocking reagent,
50 mg ml1 denatured salmon testis DNA). Hybridisation was
carried out with 1 106 c.p.m. FGFR3IIIS riboprobe/ml of the
hybridisation buffer overnight at 421C. After hybridisation,
membranes were sequentially washed at room temperature (RT)
twice for 30 min in 2 SSC, 0.1% SDS, followed by two washes in
1 SSC, 0.1% SDS.
Detection of FGFR3IIIS in normal human tissues
cDNA reverse transcribed from 24 different human tissues (brain,
heart, kidney, spleen, liver, colon, lung, small intestine, muscle,
stomach, testis, placenta, salivary gland, thyroid gland, adrenal
gland, pancreas, ovary, uterus, prostate, skin, peripheral blood
lymphocytes, bone marrow, foetal brain and foetal liver) in a 96-
well plate format (Origene Technologies, Rockville, MA, USA) was
amplified by PCR using the conditions described above and primer
set 3. PCR products (20ml) were separated by electrophoresis on a
1% agarose gel in 1 TBE. Gels were stained with ethidium
bromide (0.5mg ml1) and visualised under UV light. The quality
of cDNA for PCR was confirmed by amplification for the house-
keeping gene b2-microglobulin.
Protein expression and localisation of FGFR3IIIc and
FGFR3IIIS
Cells were lysed in lysis buffer A (50 mM NaCl, 0.05%. (v v1) NP-
40, 0.5% (w v1) sodium deoxycholate, 100 mM phenylmethyl-
sulponyl fluoride (Sigma, Poole, UK)) and incubated on ice for
20 min with occasional vortexing. Cell debris was pelleted by
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centrifugation at 11 600 g for 10 min at 41C and the supernatant
lysate was retained. The protein content of lysates was estimated
using the Bio-rad DC Protein Assay (Bio-rad, Hemel Hempstead,
UK). Protein samples (20– 60 mg) were resolved by SDS–PAGE in
an SDS electrophoresis buffer (25 mM Tris-HCl, pH 8.3, 250 mM
glycine, 0.1% (w v1) SDS) at 200 V, and electrophoretically
transferred on to a Hybond C membrane (Amersham). To confirm
equal loading of protein, duplicate samples were separated by SDS–
PAGE and stained with silver salts (Pharmacia, St Albans, UK).
All blocking, antibody incubation and wash steps were carried out
with gentle agitation. The non-specific binding of antibodies was
reduced by incubating nitrocellulose membranes in 5% (w v1)
nonfat dried skimmed milk (Marvel; NHS supplies authority) in
Tween 20-Tris-buffered saline (TTBS; 20 mM Tris-HCl pH 7.5,
500 mM NaCl, 0.05% (v v1) Tween 20 (Sigma)) for 2 h at RT.
Membranes were incubated with a polyclonal antibody raised
against a peptide to the carboxyl terminus of FGFR3 (SC-123, 1 : 200;
Santa Cruz Biotechnology Inc., Santa Cruz, California, USA) in
TTBS containing 1% (w v1) nonfat dried milk for 2 h at RT; the
signal was detected using an HRP-conjugated secondary antibody
(1 : 2000; Dako, High Wycombe, UK) for 45 min at RT and enhanced
chemiluminescence (ECL, Amersham Biosciences (UK) Ltd, Bucks,
UK). A negative control blot was incubated with the secondary
antibody alone, to check for nonspecific binding of the secondary
antibody. The high degree of homology between FGFR3IIIc and
FGFR3IIIS has so far prevented the production of antibodies specific
to these individual proteins; however, the specificity of SC123
binding to FGFR3-related proteins was evaluated by preincubation
of the antibody with blocking peptides to FGFR1 (SC-121P
50mg ml1, Santa Cruz Biotechnology Inc.) or FGFR3 (SC-123P
50mg ml1, Santa Cruz Biotechnology Inc.) for 10 min at RT prior to
incubation with the Western blot. Total protein was determined
using a pan-ERK mouse monoclonal antibody (0.25mg ml1;
BDBioscience-Transduction Laboratories, Cowley, UK).
The effect of bFGF (10mml1) and aFGF (10 ng ml1) in the
presence of heparin (10 U ml1), on the expression of FGFR3IIIc
and FGFR3IIIS after 48 h was examined in seven cell lines (SK-N-
SH, RD-ES, SKES1, TC-32, TTC466, A673 and MCF7) by Western
blot. The localisation of both proteins was investigated in TC-32
cells under normal growth conditions and in the presence of bFGF
(10 ng ml1) by differential centrifugation and Western blot. Cells
were lysed in lysis buffer B (10 mM Tris-HCl pH7.4, 0.001 M EDTA,
10 g ml1 aprotinin, 100 g ml1 leupeptin), an aliquot was taken for
total protein analysis and the nuclear, mitochondrial, plasma
membrane, ribosomal and soluble protein fractions were prepared
(Figure 4D). The identity of the mitochondrial fraction was
confirmed by blotting for cytochrome c (0.4 mg ml1, 17 kDa;
PharMingen, San Diego, CA, USA) and that of the nuclear and
ribosomal fractions for Nucleoporin p62 ( 1: 1000, 62 kDa; Trans-
duction Laboratories).
Activation of FGFR3 and FGFR1 following exposure to
aFGF and bFGF
The effect of aFGF (0.1– 10 ng ml1) and bFGF (0.1–10 ng ml1) on
tyrosine phosphorylation of FGFR1 and FGFR3 in TC-32 cells was
examined by immunoprecipitation and Western blot. TC-32 cells
were grown in low serum conditions (0.5% FCS in RPMI 1640
media) for 24 h, and then treated with either aFGF (0.1, 1 or
10 ng ml1) or bFGF (0.1, 1 or 10 ng ml1) in low serum media
containing heparin (10 U ml1) for up to 30 min at 371C. Heparin
was included in conditions for FGF treatment as its molecular
association with FGF and its receptors is reported to be essential
for biological activity (Rapraeger et al, 1991; Lin et al, 1999). Flasks
were placed in ice, cells were washed in cold PBS and lysates were
prepared in lysis buffer (50 mM HEPES (pH 7.5), 100 mM NaCl,
1 mM EGTA, 1 mM DTT, 10 mM MgCl2, 1% (v v
1) Triton X-100,
10mg ml1 aprotinin, 10 mg ml1 leupeptin, 1 mM sodium orthova-
nadate (Sigma), 25 mM sodium fluoride (Sigma)). The cell lysate
(200mg) containing 10% (w v1) SDS was denatured by heating at
1001C and immediately placed on ice. Rabbit polyclonal antibodies
to FGFR1 (5 mg SC121; Santa Cruz Biotechnology Inc) or FGFR3
(5mg SC123; Santa Cruz Biotechnology Inc.) and 30 ml of protein A
sepharose CL-4B (50% (v v1) slurry in 20 mM sodium phosphate,
pH 7.0; Pharmacia) were added to the cooled cell lysate and
incubated overnight with rotation at 41C. At 41C sepharose was
pelleted by centrifugation at 11 600 g for 5 min, the supernatant
was discarded and the pellet was washed three times in 1 ml of ice-
cold PBS containing 0.1% (w v1) SDS. Immunoprecipitated
proteins were isolated by heating samples for 5 min at 1001C in
SDS sample buffer (100 mM Tris-HCl pH 6.8, 200 mM DTT, 4%
(w v1) SDS, 0.2% (w v1) bromophenol blue, 20% (v v1) glycerol)
and analysed by SDS– PAGE and Western blot using anti-
phosphotyrosine monoclonal IgG (0.5 mg ml1; Upstate Biotech-
nology (UK) Ltd, Bucks, UK) as above, except that membranes
were blocked in 1% (w v1) BSA in TTBS and both primary and
secondary antibodies were diluted in 0.1% (w v1) BSA in TTBS.
The cell extract from A431 after treatment with the epidermal
growth factor was included as a positive control for the tyrosine
phosphorylation antibody. The optimal concentration of all
antibodies was determined empirically. An immunoprecipitation
control with no primary antibody was used to determine
nonspecific binding of proteins to the sepharose.
The activation of ERK was not measured directly, but by
immunoblotting for total ERK protein and looking for a shift in
mobility as the protein is activated. The total cell lysate (50 mg) was
separated on a 15% (w v1) low bis-SDS-polyacrylamide gel; the
final percentage of acrylamide in the resolving gel had a ratio of
acrylamide:N,0N-methylene bisacrylamide of 200 : 1 (Anachem).
The anti-pan-ERK antibody was used at 0.25 mg ml1 (BD
Biosciences-Transduction Laboratories Cambey, UK).
Knockout of FGF3IIIS in TC-32 cells
The expression of the FGFR3IIIS protein was reduced in TC-32
cells using one HPLC-purified antisense 24-mer oligonucleotide
targeted to the breakpoint between exons 7 and 11 of FGFR3IIIS
(exon 7 ACCGTGCTCAAG:GTGTCCCTGGAG exon 11; : ¼
breakpoint) to maximise the inhibition of FGFR3IIIS translation
compared to that of FGFR3IIIc. Conditions for optimum cellular
uptake of antisense oligonucleotides were established using an
FITC-labelled oligonucleotide (Biognostik, TCS Biologicals, Buck-
ingham, UK; Schlingensiepen et al, 1997). In brief, TC-32 cells
(2.5 105) were plated in primeria six-well plates and allowed to
adhere overnight in normal growth media plus 10% FCS. At time
zero (0 h), media was replaced with normal media plus 1% FCS
containing (i) HPLC-purified antisense FGFR3IIIS 24-mer at 1 mM,
(ii) HPLC-purified random scrambled oligonucleotide 24-mer at
1 mM or (iii) no oligonucleotide. Oligonucleotides were replenished
in cell cultures 24 and 48 h after initial incubation (0 h). Cells were
harvested 24, 48 and 72 h after incubation and an aliquot from each
well was taken for viable cell counting using a Neubauer
haemocytometer and the trypan blue-exclusion assay. The effect
of antisense FGFR3IIIS and random scrambled oligonucleotides on
viable cell number with time was evaluated using ANOVA and
posthoc tests (Tukey– Kramer multiple comparisons test). The
remaining cells for each condition were pooled and cell lysates
were prepared for SDS–PAGE and Western blot using FGFR3
antibodies (see above) to monitor the effect of the oligonucleotides
on FGFR3IIIS expression.
RESULTS
Detection of FGFR3 by RT– PCR
A single PCR product was generated in the MCF-7 breast
carcinoma (a) and TC-32 ESFT (b) cell lines (Figure 1A; I) using
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primer set 1 designed to amplify the first Ig-like loop of the
extracellular domain (Avivi et al, 1993). A product of the same size
and identity was also detected in the neuroblastoma cell lines SK-
N-SH and IMR-32, and the ESFT cell lines RD-ES, A673 and SK-N-
MC studied (results not shown).
Primer set 2 designed to amplify across the third Ig-like loop of
the extracellular domain, the transmembrane domain and part of
the tyrosine kinase domain generated up to three distinct PCR
products (Figure 1A; K). The expected full-length product
(FGFR3IIIc) was detected in the TC-32 ESFT cells, but not in the
MCF-7 cells. Two smaller products were detected in the MCF-7 and
TC-32 cell line RNA; the most abundant of these (FGFR3IIIS) was
isolated for further characterisation.
Characterisation of an alternatively spliced FGFR3IIIc gene
product, FGFR3IIIS
The sequence of the FGFR3IIIS PCR product was 100% identical to
the full-length FGFR3IIIc except for a 336 bp deletion resulting in
the loss of exons 9 and 10 and a 30 bp deletion in exon 7
(Figure 1B). These deletions resulted in an in-frame coding region,
consistent with the hypothesis that this is a splice-variant of
FGFR3IIIc. The sequence identity of FGFR3IIIS was confirmed in
MCF7 breast carcinoma and the Ewing’s sarcoma cell lines studied.
Exon 9 codes for the second half of the third Ig-like loop,
suggesting loss of the loop structure in this region, and exon 10
encodes the transmembrane region. The 30 bp deletion in exon 7
results in the loss of a region between the second and third Ig-like
loops, and includes a potential glycosylation site (Figure 1B).
Expression of FGFR3IIIS mRNA in normal human tissue,
cultured tumour cell lines and tumour tissue
FGFR3IIIS was detected by PCR (using primer set 3) in heart (b),
placenta (l) and ovary (q) cDNAs at low levels (Figure 2A); this was
confirmed by Southern blot using an FGFR3IIIS-specific riboprobe
(Figure 2B). RT–PCR on newly prepared total RNA extracted from
the human adrenal, brain, kidney, liver, placenta and pericardium
confirmed the expression of FGFR3IIIS only in the placenta and
pericardium (results not shown). The quality of RNA and cDNA
for RT–PCR and PCR, respectively, was confirmed by amplifica-
tion for the house-keeping gene b2-microglobulin (Figure 2C).
FGFR3IIIS was detected by RT– PCR (using primer set 2) in a
high proportion of human tumour cell lines and primary tumours.
Interestingly, it was expressed in a higher proportion of primary
tumours (57%; 17 out of 30) than the full-length FGFR3IIIc (13%;
four out of 30). Full-length FGFR3IIIc was detected in three out of
the 12 Ewing’s sarcomas and one of the two Wilms’ tumours; it was
IK
babaM
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FGFR3IIIS
A
1 3 4 5 6 7 9 10 11 12 13 14
1
2
2 3 4 5 6 7
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11 12 13
= deletion
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14 15 16 17 18-19
SP
SP = signal peptide
= glycosylation site
= ATP-binding site
= autophosphorylation site
= unsequenced region of splice variant
Split tyrosine kinase domainTM
TM = transmembrane domain
Ig-1 Ig-2 Ig-3
Ig = immunoglobulin-like loop
B
Figure 1 Identification and characterisation of a novel FGFR3IIIc variant, FGFR3IIIS. (A) The FGFR3 extracellular domain, first Ig-like loop (I) and the
transmembrane/intracellular domain (K) was amplified in the breast carcinoma MCF-7 (a) and Ewing’s sarcoma TC-32 (b) cell lines by RT–PCR. M¼fX174
RF DNA/HaeIII molecular weight marker. (B) Diagrammatical representation of FGFR3IIIc, FGFR3IIIS and the domains that each exon codes for. The split
tyrosine-kinase domain is represented as one domain, since it is not known as to which exon codes for the region between the two domains. Sequence
analysis of FGFR3IIIS demonstrated loss of exons 9 (encoding the second half of the third Ig-like domain) and 10 (coding for the transmembrane domain)
and a 30 bp deletion in exon 7 (within the region between the second and third Ig-like loops, including a potential glycosylation site). Primers were designed
in exons 3 and 4 to amplify the first Ig-like loop of the extracellular domain (primer set 1) and within exons 6 and 12 (primer set 2) to amplify the third Ig-like
loop and the transmembrane/tyrosine kinase domain.
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not detected in the neuroblastoma, rhabdomyosarcoma, astro-
cytoma or medulloblastoma samples. However, FGFR3IIIS was
detected in nine of the 12 Ewing’s sarcomas, two of the nine
neuroblastomas, three of the four medulloblastomas, both of the
Wilms’ tumours and one of the rhabdomyosarcomas (Figure 3).
One Ewing’s sarcoma and one neuroblastoma taken at relapse
expressed FGFR3IIIS but not FGFR3IIIc; FGFR3IIIS and FGFR3IIIc
were not detected in a neuroblastoma taken post-treatment
(although the RNA was successfully amplified for b2-microglobu-
lin).
FGFR3IIIS was also detected in 15 out of 19 cell lines; the IMR-
32 and SK-N-SH (neuroblastoma), RD-ES, TC-32, SK-N-MC,
SKES1 and TTC-466 (tumours of the Ewing’s sarcoma family),
ST118 (neurofibrosarcoma), RT112 (bladder carcinoma), LNCAP
(prostate carcinoma), CCL136 and RH30 (rhabdomyosarcomas),
VUP (melanoma), HT29 (colorectal carcinoma) and MCF7 (breast
carcinoma) cell lines were all positive (Figure 3B). FGFR3IIIS was
not detected in PC12, EJ, A673 and U266 cell lines.
FGFR3IIIS mRNA encodes a protein that is coexpressed
with FGFR3IIIc
FGFR3IIIS mRNA has 100% sequence homology with that of
FGFR3IIIc, except in this novel variant 30 bp of exon 7, and the
complete exons 9 and 10 sequence are deleted. The missing
sequence causes exon 7 to be directly spliced to exon 11, but leaves
the coding region in-frame, suggesting that FGFR3IIIS may code
for a novel FGFR3 protein. This is in direct contrast to the aberrant
FGFR3 cDNAs, FGFR3 AT-II and FGFR3 AT-I identified in
colorectal cancer cells, where the predicted translation products
exhibit frame-shifts and a premature termination codon in exon 10
(Jang et al, 2000).
Consistent with this hypothesis, a protein of approximately
110 kDa was identified on Western blot using the SC123 FGFR3
polyclonal antibody in the cell extract from TC-32 cells (Figure 4A).
This protein product was not detected in U266 cells (Figure 4A),
correlating with the absence of the FGFR3IIIS splice-variant mRNA
in these cells (Figure 3B). The FGFR3IIIS protein was expressed in
37% (seven out of 19) of the cell lines studied; very high levels were
detected in RT112 cells, moderate expression in TC-32, SK-N-MC,
HT-29 and MCF7 cells and low expression in RD-ES cells. Binding
of SC123 to wild-type FGFR3IIIc and this 110 kDa protein was not
inhibited by incubation with an FGFR1-blocking peptide, but was
decreased following incubation with an FGFR3-blocking peptide
(Figure 4B), suggesting SC123 was binding specifically to FGFR3
proteins. The FGFR3IIIS protein product (110 kDa) was predomi-
nantly expressed in the membrane fraction of TC-32 cells
(Figure 4C), suggesting that it may regulate biological activity
and signal transduction of FGFR3 and its variants in these
malignant cells.
Decreased soluble FGFR3IIIc and FGFR3IIIS protein
expression after exposure to bFGF but not aFGF
Although FGFR3IIIS is predominantly expressed in the
membrane fraction, it is also co-expressed with FGFR3IIIc in the
soluble fraction of TC-32 cells under normal growth conditions
(Figure 4C, CONTROL). Following treatment with bFGF
(10 ng ml1) for 48 h, the expression of soluble FGFR3IIIc and
FGFR3IIIS proteins was lost when detected by Western blot
(Figure 4C, þ bFGF), although the expression of the membrane-
associated FGFR3IIIS protein was unchanged. Following exposure
of TC-32 cells to lower concentrations of bFGF (0.1–1 ng ml1)
there was no change in the expression or localisation of FGFR3IIIS
or FGFR3IIIc (results not shown). Cellular levels and subcellular
localisation of FGFR3IIIS and FGFR3IIIc were unchanged in TC-32
cells after treatment with aFGF (0.1– 20 ng ml1)(results not
shown).
FGFR3IIIS
FGFR3IIIS
a c d l m n p q ye g h i j k r s t u v w x
B2-M
A
B
C
b of
Figure 2 FGFR3IIIS is rarely expressed in normal human tissue.
Expression of the FGFR3IIIS was examined by RT–PCR using primer set
3 (A) and Southern blotting using an FGFR3IIIS-specific probe (B) in a
number of normal human tissues. FGFR3IIIS was amplified using a primer
specific to the FGFR3IIIS sequence at the exon seven out of 11 splice site,
paired with a primer at the 50 (exon 2) or 30 (exon 17) ends of the
published wild-type FGFR3IIIc sequence. Low-level expression of the
FGFR3IIIS was detected in the heart (b), placenta (l) and ovary (q). The
probe also bound nonspecifically (product identified in the reverse
transcriptase negative control; not shown) to a smaller product in the
thyroid gland (n). RT–PCR for the house-keeping gene b2-microglobulin
(b2-m) confirmed the quality of cDNA for amplification (C) a, brain; b,
heart; c, kidney; d, spleen; e, liver; f, colon; g, lung; h, small intestine; i, Muscle;
j, stomach; k, testis; l, placenta; m, salivary gland; n, thyroid gland; o, adrenal
gland; p, pancreas; q, ovary; r, uterus; s, prostate; t, skin; u, peripheral blood
lymphocytes; v, bone marrow; w, foetal brain; x, foetal liver: RNA from the
MCF-7 cell line was included as a positive control (y).
FGFR3IIIS
a c d Me f g h i j k
RT+ve
RT−ve
A
FGFR3IIIS
FGFR3IIIS
RT−veFGFR3IIIS
B
b
a c d Me g h i j k Ml nmfb o p
RT+ve
Figure 3 Expression of FGFR3IIIc and FGFR3IIIS in tumour cell lines and
primary tumours. Expression of FGFR3IIIc (detected by RT–PCR using
primer set 2) was rare in the tumour cell lines and tumours examined;
however, the splice variant FGFR3IIIS was expressed in 57% (17 out of 30)
of tumours (a) and 79% (15 out of 19) of the tumour cell lines (b)
examined. The quality of RNA from cell lines and tumours was confirmed
by amplification for the house-keeping gene b2-microglobulin (results not
shown). (A) RT-PCR for FGFR3IIIS (a) rhabdomyosarcoma, (b) Wilms’
tumour, (c) astrocytoma, (d and j). neuroblastoma, (e–h) Ewing’s sarcoma,
(i) medulloblastoma, (k) MCF7 cell line. (B) FGFR3IIIS RT-PCR for (a)
U266, (b) IMR-32, (c) RD-ES, (d) TC-32, (e) SK-N-MC, (f) TTC-466, (g)
ST118, (h) RT112, (i) LNCAP, (j) CCL136, (k) VUP, (l) RH30, (m) PC12,
(n) EJ, (o) HT29, (p) MCF7 cell lines. M¼molecular weight markers;
RTþ ve¼ reverse transcriptase enzyme present; RT-ve¼ no reverse
transcriptase enzyme included in the reaction; negative control.
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FGFR3IIIc but not FGFR3IIIS is phosphorylated after
treatment with bFGF or aFGF
Phosphorylation of the FGFR3-precipitated protein occurred in
TC-32 cells after treatment with bFGF (0.1–1 ng ml1; þ , þ þ )
for 5–15 min (Figure 5A). The size of the precipitated, phos-
phorylated band was consistent with the identity of FGFR3IIIc
(Figure 5A’); FGFR3IIIS appeared not to be phosphorylated
following exposure to bFGF or aFGF (Figure 5A’ - -). At higher
doses of bFGF (10 ng ml1, þ þ þ ), phosphorylation of FGFR3
precipitated proteins was decreased (Figure 5A). Immunoprecipi-
tation and Western blot for FGFR3 proteins confirmed the
presence of both FGFR3 proteins in the cell lysate, suggesting that
this decrease in phosphorylation did not simply reflect the loss of
total FGFR3IIIc and FGFR3IIIS proteins from the soluble fraction
after treatment with bFGF (Figure 4A). In U266 cells that express
FGFR3IIIc but not FGFR3IIIS, the FGFR3-precipitated protein was
phosphorylated after exposure to bFGF (0.1–10 ng ml1). Unlike in
TC-32 cells, phosphorylation of FGFR3IIIc was not decreased when
10 g 20 g 30 g 10 g 20 g 30 g
U226
FGFR3IIIc
FGFR3IIIS
ERK
ERK
TC-32
− +
+
−
− −
Total fraction
600 g, 10 min
nuclei (a)
15 000 g, 5 min
mitochondria, lysosomes, peroxisomes (b)
100 000 g, 1 h
plasma membrane, microsomal fraction (c)
230 000 g, 2 h
ribosomal subunits, small polyribosomes (d)
soluble proteins
FGFR3IIIS
FGFR3IIIc
FGFR3III S
FGFR3III c
FGFR3III S
FGFR3III c
Anti-FGFR3
Anti-FGFR1
T N Mit Mem R S
CONTROL
+ bFGF
A
B
C
D
Figure 4 Variant FGFR3IIIS mRNA encodes a protein product that is
differentially expressed in TC-32 and U266 tumour cell lines, and
coexpressed with FGFR3IIIc in the membrane and soluble cell fractions.
(A) TC-32 cells expressed both FGFR3IIIS and FGFR3IIIc; the expression
was greater as the amount of cell extract analysed was increased. U226
cells did not express FGFR3IIIS, but did express FGFR3IIIc. Protein loading
was confirmed by probing for ERK (42 kDa). (B) The identity of FGFR3IIIS
and FGFR3IIIc was confirmed by incubating the TC-32 cell extract with a
blocking peptide to FGFR1 (anti-FGFR1) or FGFR3 (anti-FGFR3) prior to
SDS–PAGE and Western blot. In the presence of blocking peptide with
FGFR3, the expression of FGFR3IIIS and FGFR3IIIc as detected on Western
blot was decreased; incubation with blocking peptide for FGFR1 had no
effect on expression of either protein. Protein loading was confirmed by
probing for ERK (42 kDa). (C) FGFR3IIIS protein was coexpressed with full-
length FGFR3IIIc in the soluble and membrane fractions. Following
treatment with bFGF (10 ng ml1) for 48 h, FGFR3IIIS and FGFR3IIIc
proteins were not detected in the soluble fraction. The significance of this is
not clear. T¼ total protein extract. Fractions: N¼ nuclear,
Mit¼mitochondrial, Mem¼membrane, R¼ ribosomal, S¼ soluble. (D)
Summary of the differential centrifugation method to prepare subcellular
fractions.
aFGF
bFGF
IP FGFR3
− − −
− − −+ ++ +++
+ ++ +++
aFGF
bFGF
− − −
− − −+ ++ +++
+ ++ +++
Blot Tyrp
IP FGFR3
Blot FGFR3
IP FGFR1
Blot Tyrp
IP FGFR1
Blot FGFR1
Blot ERK
A
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C
Figure 5 Phosphorylation of FGFR3IIIc but not FGFR3IIIS after exposure
of TC-32 cells to bFGF or aFGF. (A) After treatment of TC-32 cells with
bFGF (0.1 ng ml1; þ ) or bFGF (1 ng ml1 ;þ þ ) for 10 min FGFR3IIIc
protein, immunoprecipitated (IP) with FGFR3 antibodies, was tyrosine
phosphorylated (’;IP FGFR3 Blot Tyrp). At higher doses of bFGF
(10 ng ml1; þ þ þ ), FGFR3IIIc was poorly phosphorylated. Exposure to
aFGF (0.1–10 ng ml1) induced tyrosine phosphorylation of FGFR3IIIc.
There was no evidence of tyrosine phosphorylation of FGFR3IIIS (’ - -).
Immunoprecipitation and Western blotting for FGFR3 proteins (IP FGFR3
Blot FGFR3) confirmed the presence of FGFR3IIIc and FGFR3IIIS. (B)
FGFR1 (’) was phosphorylated after exposure to bFGF (0.1, 1 or
10 ng ml1; þ , þ þ or þ þ þ ) or aFGF (0.1, 1 or 10 ng ml1; þ , þ
þ or þ þ þ ) for 10 min demonstrated by immunoprecipitation for
FGFR1 and Western blotting for tyrosine-phosphorylated proteins (IP
FGFR1 Blot Tyrp). Immunoprecipitation and Western blotting confirmed
the presence of the total the FGFR1 protein (IP FGFR1 Blot FGFR1). (C)
Following exposure of TC-32 cells to bFGF or aFGF the intracellular
signalling protein ERK was activated, demonstrated by a mobility shift of the
protein detected by Western blot (Blot ERK).
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U266 cells were exposed to higher concentrations of bFGF
(10 ng ml1), suggesting the FGFR3IIIS may modulate phosphor-
ylation of FGFR3IIIc. This requires further investigation. The
treatment of U266 cells with bFGF had no effect on the subcellular
localisation of FGFR3IIIc (results not shown).
The exposure of TC-32 cells to bFGF (0.1–10 ng ml1) or aFGF
(0.1– 10 ng ml1) induced phosphorylation of FGFR1-immunopre-
cipitated proteins (Figure 5B), and phosphorylation appeared
greatest after exposure to bFGF rather than aFGF. The treatment of
TC-32 cells with either bFGF or aFGF resulted in activation of the
intracellular signalling protein ERK (Figure 5C).
Knockout of FGFR3IIIS is associated with growth arrest of
TC-32 cells in vitro
Wild-type TC-32 cells express FGFR3IIIS, detected by Western blot
(Figure 4A). Random scrambled 24-mer oligonucleotides actively
taken up by TC-32 cells had no effect on growth (determined by
counting viable cell number) of wild-type TC-32 cells (Figure 6A).
However, delivery of an antisense FGFR3IIIS 24-mer (1 mM) over
three consecutive days was associated with a decrease in viable TC-
32 cell number compared to that in cell cultures grown under
normal growth conditions (at 48 h Po0.001, q¼ 13.3; at 72 h
Po0.001, q¼ 20.2) or in the presence of the random scrambled
oligonucleotide (at 48 h Po0.001, q¼ 13.1, at 72 h Po0.001,
q¼ 18.0) (Figure 6A). The FGFR3IIIS protein was preferentially
decreased compared to FGFR3IIIc 24, 48 and 72 h after incubation
with the antisense FGFR3IIIS 24-mer at 1 mM (Figure 6B). In the
presence of the random scrambled 24-mer oligonucleotide (1mM
for 48 h), FGFR3IIIS and FGFR3IIIc proteins were detected. These
observations suggest that FGFR3IIIS may act as a dominant
negative, inhibiting FGFR3-induced growth arrest and possibly
differentiation. This hypothesis requires further investigation.
DISCUSSION
Using RT–PCR a novel splice variant of FGFR3, missing 30 base
pairs within exon 7 encoding a region between the second and
third Ig-like loops of the extracellular domain (this contains a
potential glycosylation site), the second half of the third Ig-like
loop (including a disulphide bond site) and the transmembrane
domain has been identified. The sequence encoding the protein
kinase domains of this receptor is identical to that of wild-type
FGFR3. An FGFR3 splice variant similar to that of FGFR3IIIS, with
a deletion (bases 933–1269) overlapping that of FGFR3IIIc (bases
969– 1315), has previously been described in normal breast
epithelial and breast tumour cell lines (Johnston et al, 1995). This
deletion was reported to result in loss of exons 7 and 8.
Unfortunately, this splice variant was not fully sequenced so it is
not possible to compare it directly with that of FGFR3IIIS or the
published FGFR3 mRNA sequence (accession number M58051).
Unlike recently described nonsense transcripts of FGFR3 (Jang
et al, 2000), the coding region of FGFR3IIIS remains in-frame
resulting in a novel FGFR3 protein product that is expressed in the
membrane and soluble cell fractions.
The expression of this novel protein FGFR3IIIS in the soluble
fraction is consistent with previous studies suggesting that deletion
of the transmembrane domain of FGFR3 generates a soluble form
of the receptor (Johnston et al, 1995). However, FGFR3IIIS is
predominantly expressed in the membrane fraction under normal
growth conditions, suggesting a potential role in regulating
membrane-associated FGFR3 activity. Unexpectedly in TC-32 cells
the full-length wild-type FGFR3IIIc, in which the transmembrane
coding region remains intact, was expressed predominantly in the
soluble fraction suggesting modification of its expression in the
ESFT cells. Whether this is effected through FGFR3IIIS and has a
role in malignant transformation of ESFT remains to be seen.
During the preparation of this manuscript a soluble FGFR3
isoform has been described in human SaOS-2 osteosarcoma cells
(Jang, 2002). Like FGFR3IIIS, skipping of exons 8, 9 and 10
generated an mRNA encoding an FGFR3 in which the COOH-
terminal portion of the IG-like III and transmembrane domains
are deleted. The significance of the additional 30 bp deletion in
exon 7 of FGFR3IIIS is not clear, although loss of the potential
glycosylation site in this region suggests that it may alter
glycosylation of the protein. The presence of soluble transcripts
of FGFR4 have also recently been described and implicated in the
modulation of FGF in MCF7 breast cancer cells (Ezzat et al, 2001),
suggesting that soluble FGFRs may be a feature of tumour cells
where they disrupt the FGF/FGFR function.
The disrupted regulation of mRNA processing is a feature of
neoplastic transformation (Haber et al, 1993; Yamaguchi et al,
1994; Sager, 1997), consistent with the high frequency of
FGFR3IIIS transcripts detected in tumour but not normal
cells. Alternatively, spliced variants in tumour cells are usually
rapidly degraded through the so-called nonsense-mediated
decay pathway, to prevent the synthesis of incomplete and
potentially harmful proteins. However, in some genetic diseases
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Figure 6 Knockout of FGFR3IIIS is associated with a decrease in viable
TC-32 cell number in vitro (A) TC-32 cells treated with FGFR3IIIS antisense
(m) in the presence of reduced FCS showed reduced viable cell number 48
and 72 h after addition of antisense compared to TC-32 cells treated with a
random scrambled 24-mer oligonucleotide ( ; po0.001) or cells cultured
under normal growth conditions, that is, no oligonucleotide ( ; po0.001).
(B) Antisense FGFR3IIIS (AS; 0.5 and 1mM) reduced the level of FGFR3IIIS
expression 48 h after treatment compared to expression in TC-32 cells
treated with a random scrambled oligonucleotide (S; 0.5 and 1.0 mM) or no
oligonucleotide (C). Antisense FGFR3IIIS (AS; 1 mM) or the random
scrambled oligonucleotide (S; 1mM) was added to the TC-32 cell cultures
at 0, 24 and 48 h. FGFR3IIIS expression was inhibited in cultures treated
with antisense FGFR3IIIS (AS) compared to those treated with the random
scrambled oligonucleotide(S) at 24, 34, 48 and 72 h.
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the nonsense-mediated decay pathway is inactivated, stabilising
the alternatively spliced transcripts (Culbertson, 1999). In color-
ectal cancer, FGFR3 transcripts are readily detected by RT–PCR
(Jang et al, 2000); these may have escaped the nonsense-mediated
decay pathway or may be the breakdown products from larger
RNA transcripts, although a frame-shift means that they do not
produce protein products. In contrast, the FGFR3IIIS transcript
described in this paper has an intact open-reading frame encoding
a protein product detected by Western blot using an FGFR3
antibody to the COOH domain.
This novel protein appears to modulate the FGFR3 gene
function. The decreased growth of TC-32 cells following knockout
of FGFR3IIIS is consistent with the hypothesis that FGFR3IIIS may
compete with FGFR3 and/or its variants to antagonise their
function, for example, growth arrest and differentiation. These
observations are consistent with the putative role of FGFR3 as a
regulator of differentiation (Govindarajan and Overbeek, 2001;
Ornitz, 2001), and previous studies suggesting FGFR’s lacking a
transmembrane domain disrup the FGFR gene function in vivo
through a dominant-negative mechanism (Peters et al, 1994; Celli
et al, 1998). The decreased expression of FGFR3 variants in the
soluble fraction after exposure to bFGF implies that FGFR3IIIS
may regulate FGF trafficking within the cell or act as a negative
feedback mechanism sequestering FGF away from cell surface
receptors; on the other hand, alternative splicing in the Ig-like
domain III may create receptors with different ligand-binding
preferences (Chellaiah et al, 1994; Lin et al, 1997). Further studies
are required to investigate these possibilities. As with other
tyrosine kinase receptors, FGFRs are activated by dimerisation
resulting in autophosphorylation and subsequent recruitment of
intracellular signalling proteins. Preliminary evidence supports the
hypothesis that FGFR3IIIS may modulate the activation and
trafficking of other FGFRs, although remaining unphosphorylated
itself. These hypotheses and characterisation of ligand interactions,
including those of the most selective FGFR3 ligand FGF8, require
further investigation.
In summary, we have described alternative splicing of FGFR3 in
the third Ig-like loop of the extracellular domain to generate a
novel spliced variant of FGFR3IIIc, FGFR3IIIS, frequently ex-
pressed in tumour but rarely in normal cells. This appears to code
for a receptor that may act as a dominant negative to modulate the
activation and trafficking of FGFs and FGFRs, influencing cell
growth and phenotype. Our results support the hypotheses that
alternative splicing of the FGFR3 Ig-domain III may contribute to
malignant transformation, and represents a mechanism for the
generation of receptor diversity.
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